13th Oct 2020 13:54
Sareum Holdings PLC - Cambridge-based specialist drug development company focused on cancer and autoimmune diseases - Pretax loss narrows in financial year ended June 30 to GBP1.1 million from GBP1.7 million a year prior. Administration expenses reduced to GBP1.1 million from GBP1.7 million. Reports revenue of GBP47,204, versus none year before. Does not declare a dividend, unchanged. Expects to report on continued progress with its internal, proprietary programmes and its licensed programmes during the coming year.
Current stock price: 1.42 pence
Year-to-date change: up over 100%, trading at 0.36 on Dec 31, 2019
By Greg Roxburgh; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Sareum